| Previous Close | 70.48 |
| Open | 71.24 |
| Bid | 70.61 x 900 |
| Ask | 70.82 x 200 |
| Day's Range | 69.84 - 71.37 |
| 52 Week Range | 63.76 - 88.85 |
| Volume | 22,911,223 |
| Avg. Volume | 8,319,178 |
| Market Cap | 92.15B |
| Beta | 0.97 |
| PE Ratio (TTM) | 7.45 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.95%) |
| Ex-Dividend Date | 2017-06-14 |
| 1y Target Est | N/A |
- Motley Fool•8 hours ago
2 Top Biotech Stocks to Buy on Sale
Bargain hunters may want to check out these two top biotech stocks right now.
- TheStreet.com•yesterday
Is Gilead Sciences on the Verge of a Powerful Rally?
Time for this one to pop.
- Barrons.com•yesterday
[$$] Gilead Is Finally a Buy: 'Value Trap No More'
It’s been a bumpy year for Gilead, but biotechs have staged a fierce rally this week amid a growing sense that the Trump administration will not push aggressively for drug companies to lower prices. Given this favorable backdrop, Gilead’s rock-bottom valuation, 3% yield and price-momentum, we like the stock under $70. On Friday, analyst Andrew Peters and his team initiated coverage on Gilead Sciences (GILD) with a Buy rating and $79 price target.
